PACB - Pacific Biosciences of California, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.34
+0.06 (+0.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.28
Open7.27
Bid7.30 x 3000
Ask7.40 x 1000
Day's Range7.23 - 7.35
52 Week Range2.02 - 7.84
Volume1,353,470
Avg. Volume4,305,542
Market Cap1.098B
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • LMNX or PACB: Which is a Better MedTech Investment Pick?
    Zacks17 days ago

    LMNX or PACB: Which is a Better MedTech Investment Pick?

    Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.

  • Here's Why You Should Hold Pacific Biosciences (PACB) Now
    Zacks2 months ago

    Here's Why You Should Hold Pacific Biosciences (PACB) Now

    Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.

  • Pacific Biosciences of California Has Seen Solid Growth in 2018
    Market Realist2 months ago

    Pacific Biosciences of California Has Seen Solid Growth in 2018

    Pacific Biosciences of California stock rose from $2.64 at the close of market on December 29, 2017, to $7.47 at the close of market on November 21, 2018, representing a ~183% year-to-date rise. PACB hit its 52-week high of $7.84 on November 8. On November 1, Pacific Biosciences entered into an agreement with Illumina (ILMN) wherein Illumina agreed to acquire it.

  • Here's Why You Should Invest in Illumina (ILMN) Stock Now
    Zacks2 months ago

    Here's Why You Should Invest in Illumina (ILMN) Stock Now

    llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.

  • Pacific Biosciences Offers Insights on Aedes aegypti Genome
    Zacks2 months ago

    Pacific Biosciences Offers Insights on Aedes aegypti Genome

    Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.

  • Is This the Real Reason Illumina Acquired Pacific Biosciences?
    Motley Fool2 months ago

    Is This the Real Reason Illumina Acquired Pacific Biosciences?

    The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.

  • Motley Fool2 months ago

    Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A

    Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.

  • Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
    Zacks2 months ago

    Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y

    Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.

  • Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
    Zacks2 months ago

    Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences

    Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.

  • Pacific Biosciences of California Rose 67.63% on November 2
    Market Realist3 months ago

    Pacific Biosciences of California Rose 67.63% on November 2

    On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price. On November 1, Illumina (ILMN) released a press release announcing the acquisition of Pacific Biosciences of California for a total consideration of $1.2 billion. According to the press release, Illumina expects to close the deal by mid-2019. The acquisition is expected to strengthen Illumina’s position in the genome sequencing market.

  • Here's Why Illimuna Just Bought Its Biggest Competitor
    Motley Fool3 months ago

    Here's Why Illimuna Just Bought Its Biggest Competitor

    Illumina surprised investors this week by announcing it's buying Pacific Biosciences. Here's how the deal could move the needle for investors.

  • Associated Press3 months ago

    Apple and Kraft Heinz drop while Starbucks and Symantec rise

    Stocks that moved substantially or traded heavily on Friday: Apple Inc., down $14.74 to $207.48 The company's revenue forecast disappointed Wall Street and it said it will stop reporting quarterly iPhone ...

  • Why Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today
    Motley Fool3 months ago

    Why Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today

    Find out which of these stocks got a buyout bid.

  • Why Pacific Biosciences of California Stock Is Skyrocketing Today
    Motley Fool3 months ago

    Why Pacific Biosciences of California Stock Is Skyrocketing Today

    A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.

  • Benzinga3 months ago

    Illumina Buys Rival Pacific Biosciences In $1.2B Deal

    Shares of Pacific Biosciences of California (NASDAQ: PACB ), a developer of systems for gene sequencing, are soaring to a two-year high in pre-market trading. What Happened Pacific Biosciences announced ...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...

  • Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates

    Pacific Biosciences (PACB) delivered earnings and revenue surprises of -18.75% and -17.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Pacific Biosciences of California Reports a Dismal Quarter -- and a Delightful Acquisition
    Motley Fool3 months ago

    Pacific Biosciences of California Reports a Dismal Quarter -- and a Delightful Acquisition

    A pending buyout by Illumina overshadows the gene-sequencing company's third-quarter performance.

  • Associated Press3 months ago

    Pacific Biosciences: 3Q Earnings Snapshot

    On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Illumina Inc. to buy Menlo Park-based biotech firm for $1.2 billion
    American City Business Journals3 months ago

    Illumina Inc. to buy Menlo Park-based biotech firm for $1.2 billion

    Illumina Inc. said it plans to purchase Menlo Park-based Pacific Biosciences of California Inc. for approximately $1.2 billion in a move to accelerate its scientific discovery and long-read sequencing, the company said Thursday. The all-cash transaction was set at a price of $8 per Pacific Biosciences share, with the price representing a 71 percent premium to Pacific Biosciences’ 30 trading day price, according to a statement. Illumina hopes to use the acquisition to integrate workflows and technologies "to help researchers advance their discoveries faster and clinicians offer new tests economically." “PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing,” said Francis deSouza, Illumina’s president and CEO, in the statement.

  • Reuters3 months ago

    Illumina to buy rival Pacific Biosciences in $1.2 bln deal

    Gene sequencing company Illumina Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy smaller rival Pacific Biosciences of California Inc in an all-cash deal valued at $1.2 billion, expanding its capabilities as the market grows. Illumina's offer of $8 per Pacific share represents a premium of about 77 percent to Pacific's Thursday close. Illumina is a major player in the nascent gene sequencing space and last year unveiled its NovaSeq sequencing platform, which is designed to deliver faster and cheaper gene sequencing over existing models.

  • Reuters3 months ago

    Gene sequencing company Illumina to buy Pacific Biosciences in $1.2 billion deal

    (Reuters) - Gene sequencing company Illumina Inc (ILMN.O) said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy Pacific ...

  • MarketWatch3 months ago

    Illumina to acquire Pacific Biosciences for $1.2 billion in cash

    Illumina Inc. said late Thursday that it plans to acquire Pacific Biosciences of California Inc. for $1.2 billion. Illumina stock was down less than 1% in after hours trading. Illumina said it will pay $8 per share in an all-cash deal. "[Pacific Biosciences] unmatched accuracy mirrors that of Illumina's in short-read sequencing," Illumina Chief Executive Francis deSouza said. "Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception." Goldman Sachs is serving as a financial advisor for the transaction. Illumina will hold a conference call at 5 p.m. Eastern time to discuss the transaction. Illumina stock is up 43% this year as the S&P 500 index has gained 2.5%.

  • Pacific Biosciences Introduces Enhancements to Sequel System
    Zacks3 months ago

    Pacific Biosciences Introduces Enhancements to Sequel System

    The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.

  • Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
    Zacks4 months ago

    Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

    Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.